Posttransplant lymphoproliferative disease: Pathogenesis, monitoring, and therapy

Research output: Contribution to journalArticle

Abstract

The spectrum of transplant-related lymphoproliferative diseases is expanding to include a variety of neoplasias that typically occur late after transplant including Epstein-Barr virus (EBV)-negative B- and T-cell lymphomas, EBV-positive T-cell lymphoma, myeloma, plasmacytoma, and Hodgkin's disease. New approaches to diagnosis and monitoring based on quantitative polymerase chain reaction for EBV DNA are being explored. What exactly is being measured (the source and character of the viral DNA) remains to be determined, as does the compartment that should be assayed (whole blood, serum plasma, or lymphocytes). These questions not withstanding, there is an emerging consensus that these technologies will facilitate rapid diagnosis and therapeutic monitoring in the future. A myriad of therapeutic interventions are or will become available. Rituximab, alone or in addition to other therapies, promises a profound change in the landscape with regard to the treatment and perhaps the prevention of posttransplant lymphoproliferative disease. New approaches to adoptive cellular immunotherapy, including use of EBV-specific products from unrelated donors, nonspecifically activated autologous products, and genetically engineered T cells, are all being explored.

Original languageEnglish (US)
Pages (from-to)359-363
Number of pages5
JournalCurrent Oncology Reports
Volume5
Issue number5
StatePublished - Sep 2003

Fingerprint

Human Herpesvirus 4
T-Cell Lymphoma
Transplants
Adoptive Immunotherapy
Unrelated Donors
Plasmacytoma
Viral DNA
B-Cell Lymphoma
Therapeutics
Hodgkin Disease
Lymphocytes
Technology
T-Lymphocytes
Polymerase Chain Reaction
DNA
Serum
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Posttransplant lymphoproliferative disease : Pathogenesis, monitoring, and therapy. / Ambinder, Richard F.

In: Current Oncology Reports, Vol. 5, No. 5, 09.2003, p. 359-363.

Research output: Contribution to journalArticle

@article{d79180aafada4268a01b3bc8bc908bfb,
title = "Posttransplant lymphoproliferative disease: Pathogenesis, monitoring, and therapy",
abstract = "The spectrum of transplant-related lymphoproliferative diseases is expanding to include a variety of neoplasias that typically occur late after transplant including Epstein-Barr virus (EBV)-negative B- and T-cell lymphomas, EBV-positive T-cell lymphoma, myeloma, plasmacytoma, and Hodgkin's disease. New approaches to diagnosis and monitoring based on quantitative polymerase chain reaction for EBV DNA are being explored. What exactly is being measured (the source and character of the viral DNA) remains to be determined, as does the compartment that should be assayed (whole blood, serum plasma, or lymphocytes). These questions not withstanding, there is an emerging consensus that these technologies will facilitate rapid diagnosis and therapeutic monitoring in the future. A myriad of therapeutic interventions are or will become available. Rituximab, alone or in addition to other therapies, promises a profound change in the landscape with regard to the treatment and perhaps the prevention of posttransplant lymphoproliferative disease. New approaches to adoptive cellular immunotherapy, including use of EBV-specific products from unrelated donors, nonspecifically activated autologous products, and genetically engineered T cells, are all being explored.",
author = "Ambinder, {Richard F}",
year = "2003",
month = "9",
language = "English (US)",
volume = "5",
pages = "359--363",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Posttransplant lymphoproliferative disease

T2 - Pathogenesis, monitoring, and therapy

AU - Ambinder, Richard F

PY - 2003/9

Y1 - 2003/9

N2 - The spectrum of transplant-related lymphoproliferative diseases is expanding to include a variety of neoplasias that typically occur late after transplant including Epstein-Barr virus (EBV)-negative B- and T-cell lymphomas, EBV-positive T-cell lymphoma, myeloma, plasmacytoma, and Hodgkin's disease. New approaches to diagnosis and monitoring based on quantitative polymerase chain reaction for EBV DNA are being explored. What exactly is being measured (the source and character of the viral DNA) remains to be determined, as does the compartment that should be assayed (whole blood, serum plasma, or lymphocytes). These questions not withstanding, there is an emerging consensus that these technologies will facilitate rapid diagnosis and therapeutic monitoring in the future. A myriad of therapeutic interventions are or will become available. Rituximab, alone or in addition to other therapies, promises a profound change in the landscape with regard to the treatment and perhaps the prevention of posttransplant lymphoproliferative disease. New approaches to adoptive cellular immunotherapy, including use of EBV-specific products from unrelated donors, nonspecifically activated autologous products, and genetically engineered T cells, are all being explored.

AB - The spectrum of transplant-related lymphoproliferative diseases is expanding to include a variety of neoplasias that typically occur late after transplant including Epstein-Barr virus (EBV)-negative B- and T-cell lymphomas, EBV-positive T-cell lymphoma, myeloma, plasmacytoma, and Hodgkin's disease. New approaches to diagnosis and monitoring based on quantitative polymerase chain reaction for EBV DNA are being explored. What exactly is being measured (the source and character of the viral DNA) remains to be determined, as does the compartment that should be assayed (whole blood, serum plasma, or lymphocytes). These questions not withstanding, there is an emerging consensus that these technologies will facilitate rapid diagnosis and therapeutic monitoring in the future. A myriad of therapeutic interventions are or will become available. Rituximab, alone or in addition to other therapies, promises a profound change in the landscape with regard to the treatment and perhaps the prevention of posttransplant lymphoproliferative disease. New approaches to adoptive cellular immunotherapy, including use of EBV-specific products from unrelated donors, nonspecifically activated autologous products, and genetically engineered T cells, are all being explored.

UR - http://www.scopus.com/inward/record.url?scp=2142859293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142859293&partnerID=8YFLogxK

M3 - Article

C2 - 12895385

AN - SCOPUS:2142859293

VL - 5

SP - 359

EP - 363

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 5

ER -